In this analysis, the composite outcome was designed to reflect the primary and secondary goals of the trial, but additional analyses could explore other outcomes, such as improvement in glycemic control constrained by the incidence of hypoglycemia, which represents a major, potentially life-threatening adverse effect of insulin intensification. The gene discussed is INS; the disease is Hypoglycemia.